Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer.

Objectives: Gonadotropin-releasing hormone agonists are widely used as androgen deprivation therapy in many men with locally advanced or metastatic prostate cancer. Gonadotropin-releasing hormone agonists are delivered by intramuscular injection every 1, 3 or 6 months, but in some patients subcutaneous injection may be more appropriate. This study assessed the efficacy and safety profile of the gonadotropin-releasing hormone agonist, triptorelin pamoate, when administered by the subcutaneous route.

[Local screening program for prostate cancer].

Objective: By massive screening of men between 50 and 75 years of age, to find those of them that are in the early stage of the carcinoma of the prostate and evaluate the usefulness of applying this method nationwide.

Patients And Methods: 183 male Pleven citizens between 50 and 75 years of age underwent clinical examination, digital rectal examination (DRE) and serum prostate-specific antigen (PSA) determination. Those with suspicious DRE or PSA > 4 ng/ml underwent further examinations: transrectal ultrasonography (TRUS) and biopsy.